---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-072382"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-06-10T20:34:18+00:00"
generated_at: "2026-06-10T20:36:17.493362+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Humacyte ATEV meets Phase 3 primary endpoint in female dialysis access; plans supplemental BLA filing H2 2026

## Summary
- ATEV patients averaged 220 catheter-free days vs 129 for AV fistula (p=0.00070), meeting superiority endpoint.
- Infection rate: 6 per 100 patient-years for ATEV vs 23 for AV fistula; no study access-associated infections in ATEV group.
- Trial enrollment will terminate; existing patients followed per protocol. Supplemental BLA targeting FDA filing in second half of 2026.
- ATEV observed to have favorable benefit-risk profile with no new safety signals; results to be presented at SVS VAM on June 11.

## SEC filing metadata
- accession: 0001104659-26-072382
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-06-10T20:34:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465926072382/0001104659-26-072382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465926072382/tm2617224d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-072382
- JSON: https://secwatch.observer/filing/0001104659-26-072382.json
- Plain text: https://secwatch.observer/filing/0001104659-26-072382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.